The Time is Ripe for a Randomized Controlled Trial of Oral Vancomycin in Primary Sclerosing Cholangitis

Clin Gastroenterol Hepatol. 2023 Sep;21(10):2699-2700. doi: 10.1016/j.cgh.2022.11.017. Epub 2022 Nov 25.

Authors

Jennifer Christine Halma¹, Laura Cristoferi², Marco Carbone²

Affiliations

¹ Division of Gastroenterology, Hepatology, and Nutrition, Department of Pediatrics, Stanford University School of Medicine, Lucile Packard Children's Hospital, Stanford, California.
² Division of Gastroenterology, Center for Autoimmune Liver Diseases, Department of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy.

PMID: 36442726
DOI: 10.1016/j.cgh.2022.11.017

No abstract available

Publication types

Randomized Controlled Trial
Letter
Comment

MeSH terms

Anti-Bacterial Agents / therapeutic use
Cholangitis, Sclerosing* / complications
Cholangitis, Sclerosing* / drug therapy
Colitis, Ulcerative* / drug therapy
Humans
Vancomycin / therapeutic use

Substances

Vancomycin
Anti-Bacterial Agents